ESSA Pharma Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q4 2020 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
ESSA Pharma Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q4 2020 to Q2 2024.
- ESSA Pharma Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$7.23M, a 0.32% increase year-over-year.
- ESSA Pharma Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2024 was -$27.6M, a 0.83% decline year-over-year.
- ESSA Pharma Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$26.6M, a 24.4% increase from 2022.
- ESSA Pharma Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$35.2M, a 4.47% increase from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)